We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients.
- Authors
Santoro, M.; Bertoli, A.; Lorenzini, P.; Ceccherini-Silberstein, F.; Gianotti, N.; Mussini, C.; Torti, C.; Perri, G.; Barbarini, G.; Bini, T.; Melzi, S.; Caramello, P.; Maserati, R.; Narciso, P.; Micheli, V.; Antinori, A.; Perno, C.
- Abstract
The protease inhibitor atazanavir (ATV) can be used either boosted by ritonavir (ATV300/r) or unboosted (ATV400). To date, however, genotypic resistance scores (GRSs) have been developed only for boosted-ATV. We have determined GRS associated with virologic response (VR) for both ATV300/r and ATV400 in highly pre-treated HIV-1 infected patients. We analyzed the results of genotypic tests available 0–3 months before the initiation of an ATV-containing regimen in 159 patients with HIV-RNA ≥ 500 copies/ml (ATV300/r group: 74; ATV400 group: 85) who were enrolled in the CARe study through an Early Access Program. The impact of baseline protease mutations on VR (≥ 1 log10copies/ml HIV-RNA decrease at 12–24 weeks) was analyzed using Fisher’s exact test. Mutated protease amino acid positions (MPP) with p < 0.20 were retained for further analysis. The GRSs were determined by a step-by-step analysis using the χ2 test for trend. The GRSs for ATV300/r and ATV400 revealed differing sets of mutations. For ATV300/r, 12 MPPs (10C/I/V + 32I + 34Q + 46I/L + 53L + 54A/M/V + 82A/F/I/T + 84V + 90M – 15E/G/L/V – 69K/M/N/Q/R/T/Y – 72M/ T/V; p = 1.38 × 10–9) were the most strongly associated with VR (VR: 100%, 78.3%, 83.3%, 75% and 0% of patients with a score of –2/–1, 0, 1, 2, and ≥ 3, respectively); the last three MPPs (I15/H69/I72) were associated with a better VR. For ATV400, nine MPPs (16E + 20I/M/R/T/V + 32I + 33F/I/V + 53L/Y + 64L/M/ V + 71I/T/V + 85V + 93L/M; p = 9.42 × 10–8) were most strongly associated with VR (VR: 83.3%, 66.7%, 5.9%, 0% of patients with 0, 1/2, 3, and ≥ 4 MPP, respectively). Differences between GRSs for ATV300/r and ATV400 may be due to different ATV drug levels (boosted vs unboosted), favoring different pathways of escape from antiviral pressure. Both GRSs were independent predictors of response in a multivariable logistic regression model. Nevertheless, cross-validation of these GRSs on different patient databases is required before their implementation in clinical practice.
- Subjects
PROTEASE inhibitors; DRUG resistance; HIV infections; THERAPEUTICS; AMINO acids; GENETIC mutation; CLINICAL medicine; LOGISTIC regression analysis
- Publication
Infection, 2009, Vol 37, Issue 3, p233
- ISSN
0300-8126
- Publication type
Article
- DOI
10.1007/s15010-008-8065-4